00:08 , May 26, 2016 |  BC Extra  |  Financial News

Arrivo debuts with $49M

Newco Arrivo BioVentures LLC (Research Triangle Park, N.C.) launched with a $49 million venture round led by Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Solas BioVentures, Rex Health Ventures and undisclosed others also participated. Arrivo plans to acquire...
07:00 , Jul 21, 2014 |  BC Week In Review  |  Clinical News

JZP-110: Phase IIb data

A double-blind, U.S. Phase IIb trial in 93 patients with narcolepsy showed that once-daily JZP-110 met the co-primary endpoints of increasing average sleep onset latency as measured by MWT (12.8 vs. 2.1 minutes, p<0.0001) and...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

Aerial, Jazz Pharmaceuticals deal

Aerial granted Jazz exclusive, worldwide rights to develop and commercialize ADX-N05, except in countries in Asia where SK Biopharmaceuticals Co. Ltd. (Seoul, South Korea) has rights. ADX-N05 has completed Phase IIb testing for...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Clinical News

ADX-N05: Phase IIa data

A double-blind, placebo-controlled, crossover, U.S. Phase IIa trial in 33 patients with narcolepsy showed that once-daily ADX-N05 met the primary endpoint of increasing sleep latency from baseline to week 2 as measured by the MWT...
07:00 , Sep 3, 2012 |  BC Week In Review  |  Clinical News

ARL-N05 regulatory update

FDA granted Orphan Drug designation to Aerial's ARL-N05 to treat narcolepsy. Aerial said it plans to begin Phase IIb testing of the compound this month, with data expected in mid-2013. ARL-N05, whose mechanism of action...
00:05 , Jul 14, 2012 |  BC Extra  |  Financial News

Aerial raises $3.8M

Aerial BioPharma LLC (Morrisville, N.C.) raised $3.8 million in the first tranche of a planned $12 million financing. The company plans to complete the financing by early 2014. New investor Rex Health Ventures joined existing...
07:00 , Oct 18, 2010 |  BC Week In Review  |  Company News

Neuronex deal

Newco Neuronex licensed from an undisclosed entity an undisclosed compound to treat epilepsy. Neuronex plans to start clinical testing by year end. Financial terms were not disclosed. Neuronex was launched by the former management team...
08:00 , Nov 23, 2009 |  BC Week In Review  |  Company News

Addrenex, Shionogi deal

Shionogi's Sciele Pharma Inc. subsidiary will acquire partner Addrenex for about $29 million in cash. Sciele already has rights to Addrenex's Clonicel clonidine to treat ADHD, Jenloga XR once-daily clonidine for hypertension and...
08:00 , Nov 12, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Adrenergic receptor a2c...
07:00 , Oct 5, 2009 |  BC Week In Review  |  Clinical News

Clonicel clonidine regulatory update

Addrenex submitted an sNDA to FDA for Clonicel clonidine to treat attention-deficit hyperactivity disorder (ADHD). Clonicel is a modified-release formulation of clonidine, an adrenergic receptor alpha 2 (ADRA2) agonist marketed for hypertension. Sciele...